UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 1177-10
Program Prior Authorization/Notification
Medication dichlorphenamide, Keveyis® (dichlorphenamide)*, Ormalvi™
(dichlorphenamide)*
P&T Approval Date 2/2016, 2/2017, 2/2018, 2/2019, 2/2020, 2/2021, 2/2022, 2/2023,
2/2024, 2/2025
Effective Date 5/1/2025
1. Background:
Keveyis® (dichlorphenamide)* is an oral carbonic anhydrase inhibitor indicated for the
treatment of primary hyperkalemic periodic paralysis, primary hypokalemic periodic
paralysis, and related variants. Ormalvi™ (dichlorphenamide)* is an oral carbonic anhydrase
inhibitor indicated for the treatment of primary hyperkalemic periodic paralysis, primary
hypokalemic periodic paralysis, and related variants.
Members will be required to meet the coverage criteria below.
2. Coverage Criteriaa:
A. Initial Authorization
1. dichlorphenamide, Keveyis*, or Ormalvi* will be approved based on one of the
following criteria:
a. Diagnosis of primary hyperkalemic periodic paralysis or related variant
-OR-
b. Diagnosis of primary hypokalemic periodic paralysis or related variant
Authorization of therapy will be issued for 12 months.
B. Reauthorization
1. dichlorphenamide, Keveyis*, or Ormalvi* will be approved based on the following
criterion:
a. Documentation of positive clinical response
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
© 2025 UnitedHealthcare Services, Inc.
1
* Keveyis (brand) and Ormalvi are typically excluded from coverage. Tried/Failed criteria may
be in place. Please refer to plan specifics to determine exclusion status.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-
10) and/or claim logic. Use of automated approval and re-approval processes varies by
program and/or therapeutic class.
• Supply limits may be in place.
4. References:
1. Keveyis® [package insert]. Chicago, IL: Xeris Pharmaceuticals, Inc.; August 2024.
2. Ormalvi™ [package insert]. Cambridge, CB3 0FA, United Kingdom: Cycle
Pharmaceuticals Ltd; February 2024.
Program Prior Authorization/Notification – dichlorphenamide, KeveyisTM
(dichlorphenamide), Ormalvi™
Change Control
2/2016 New program.
2/2017 Annual review. No changes to coverage criteria.
2/2018 Annual review. No changes to coverage criteria.
2/2019 Annual review. Updated references. Updated background.
2/2020 Annual review. Updated references. No changes to coverage criteria.
2/2021 Annual review. No changes to coverage criteria.
2/2022 Annual review. No changes to coverage criteria.
2/2023 Annual review. Added state mandate with no changes to coverage
criteria.
2/2024 Annual review. Updated reference.
2/2025 Updated initial authorization to 12 months. Added generic
dichlorphenamide and Ormalvi. Added coverage exclusion statement
for brand Keveyis and Ormalvi. Updated references.
© 2025 UnitedHealthcare Services, Inc.
2